. 2015 Aug 16;22(1):31–39. doi: 10.1111/jep.12422

Table 3.

Hazard ratios comparing each successive 6‐month period of follow‐up with rates of HRU and fracture in patients with an MPR ≥80%

Pairwise comparison between persistence groups	HRU rate, HR^* (95% CI)	Fracture rate, HR^* (95% CI)
<12 months vs. 12–<24 months	1.27 (1.15–1.41)	1.08 (0.81–1.42)
<12 months vs. 12–<24 months	P < 0.0001	P = 0.610
<12 months vs. 24–<36 months	1.16 (1.12–1.20)	1.19 (1.09–1.30)
<12 months vs. 24–<36 months	P < 0.0001	P = 0.0002
<12 months vs. ≥36 months	1.03 (1.02–1.03)	1.06 (1.04–1.09)
<12 months vs. ≥36 months	P < 0.0001	P < 0.0001
12–<24 months vs. 24–<36 months	1.26 (1.1–1.4)	1.16 (0.84–1.59)
12–<24 months vs. 24–<36 months	P = 0.0002	P = 0.3805
12–<24 months vs. ≥36 months	1.03 (1.02–1.03)	1.07 (1.04–1.09)
12–<24 months vs. ≥36 months	P < 0.0001	P < 0.0001
24–<36 months vs. ≥36 months	1.03 (1.01–1.04)	1.04 (1.00–1.08)
24–<36 months vs. ≥36 months	P = 0.0001	P = 0.0579

*HR for the interaction between each 6‐month period and HRU or fracture rate.

Multivariate modelling adjusted for age, co‐medication and co‐morbidities. For each comparison, follow‐up was from the end of the shorter persistence period.

CI, confidence interval; HR, hazard ratio; HRU, health resource utilization; MPR, medication possession ratio.